Broxinac, eye drops 0.09% 1.7ml

Bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic effects, blocks the synthesis of prostaglandins from arachidonic acid, by inhibiting cyclooxygenase 1 and 2, resulting in reduced inflammation and pain response.

In vivo studies have shown that prostaglandins mediate some types of ocular inflammation. In animal studies, prostaglandins contributed to disruption of the blood-ophthalmic barrier, increased vascular permeability, caused vasodilation, leukocytosis, and increased intraocular pressure.

Indications

The drug Broxinac is suitable for reducing postoperative inflammation as well as pain syndrome in patients after cataract extraction.

Active ingredient

Composition

The substance contains one active ingredient brombenac sodium sesquihydrate at a concentration of 0.9 mg in 1 ml of solution.

Additional components in the solution include:

Benzalkonium chloride (0.05 mg),

Polysorbate 80 (1.5 mg),

dihydrate disodium edetate (0.2 mg),

povidone K-30 (20 mg),

anhydrous sodium sulfite (2 mg),

sodium borate decahydrate (11 mg),

/p>

sodium hydroxide to create an optimal pH of 8.3,

water for injection.

The solution in the volume of 1.7 ml is placed in vials and packed in cartons.

How to take, the dosage

The drug Broxinac is injected into the conjunctival sac once a day. It is advisable to start treatment on the eve of the upcoming surgery and continue for two weeks in the postoperative period.

If for any reason the patient has missed the instillation of the agent, the drug should be instilled as soon as possible. The dose of Broxinac is maintained. If the duration of the missed instillation is close to 24 hours, then the medication should be dripped at the usual time, maintaining the usual dosage.

Interaction

The drug can be administered simultaneously with other ophthalmic agents, but the interval between instillations should be at least 5 minutes.

Special Instructions

The use of topical NSAIDs 24 hours before eye surgery and for 14 days after ophthalmic surgery may increase the risk and severity of adverse corneal reactions.

The use of topical NSAIDs may lead to the development of keratitis. In some susceptible patients, prolonged use of topical NSAIDs may cause epithelial tearing, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These side effects may pose a risk of vision loss. Patients with signs of corneal epithelium rupture should immediately discontinue use of the drug and be under medical supervision until corneal condition normalizes.

The use of NSAIDs may slow the healing process, especially when combined with topical corticosteroids. Patients should be advised that healing may be delayed while using NSAIDs.

Patients should not use contact lenses when using Broxinac.

Patients should be warned not to touch the tip of the dropper or any surface with it as this may cause contamination of the contents of the vial.

Impact on driving and operating machinery

The drug slightly affects the ability to drive and operate machinery. There may be transient blurred vision after injection of the drug, therefore it is recommended to wait until full recovery of vision before starting to drive vehicles and operate machinery.

Contraindications

Side effects

Visual disorders:

Often (observed in 2-7% of patients): feeling of discomfort and unusual sensations in the eyes, eye irritation, pain, itching and burning in the eyes, eye redness, conjunctival hyperemia, iris inflammation.

Very rare: there have been single post-marketing reports of corneal erosion, corneal perforation, corneal thinning, and epithelial destruction.

Nervous system disorders: headache.

When using 0.09% bromfenac solution twice, reactions have also been observed:

Visual disorders:

Sometimes: decreased visual acuity, retinal hemorrhage, corneal edema, photophobia, bleeding from eyelid vessels, exudates on the fundus.

Rarely: corneal ulcer,

Respiratory, thoracic and mediastinal disorders: nasal bleeding, cough, nasal discharge, asthma.

General disorders and disorders at the site of administration: facial edema.

Overdose

If the drug is accidentally administered enterally, a large volume of water should be drunk to reduce the concentration of Broxinac in the stomach.